Autologous hematopoietic cell transplantation: an update for clinicians (Q38248359)

1 September 2017

1 reference

title

Autologous hematopoietic cell transplantation: an update for clinicians (English)

1 reference

1 September 2017

Mehdi Hamadani

1

1 reference

1 September 2017

language of work or name

English

0 references

publication date

11 September 2014

1 reference

1 September 2017

1 reference

1 September 2017

volume

46

1 reference

1 September 2017

issue

8

1 reference

1 September 2017

page(s)

619-632

1 reference

How we approach patient evaluation for hematopoietic stem cell transplantation

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

The same but different: autologous hematopoietic stem cell transplantation for patients with lymphoma and HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Clinical outcomes of patients with impaired left ventricular ejection fraction undergoing autologous bone marrow transplantation: can we safely transplant patients with impaired ejection fraction?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Pulmonary function testing prior to hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Patients at risk: addressing addiction in patients undergoing hematopoietic SCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Improving stem cell mobilization strategies: future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Peripheral blood stem cell mobilization and harvesting after fludarabine therapy for low-grade lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Results of autologous stem cell transplant in multiple myeloma patients with renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Monoclonal antibodies in conditioning regimens for hematopoietic cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Management of infections complicating allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Clostridium difficile-associated disease in human stem cell transplant recipients: coming epidemic or false alarm?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Single versus double autologous stem-cell transplantation for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Clonal competition with alternating dominance in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Autologous stem cell transplantation for primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC autologous stem-cell support: still very long survival but late relapses do occur.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Therapies for peripheral T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphoma (PTCL): Analysis of Prognostic Factors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of periphera

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Lenalidomide after stem-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20( ) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Live (vaccines) from New York

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Iron overload in hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Late effects after autologous hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Image-guided total-marrow irradiation using helical tomotherapy in patients with multiple myeloma and acute leukemia undergoing hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07853890.2014.952662

10.3109/07853890.2014.952662

21 January 2018

Identifiers

DOI

1 reference

release_frik7x6e4varrhcv2j2qlu3scy

1 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/frik7x6e4varrhcv2j2qlu3scy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference